Filed for bankruptcy in Dec 2024
GRTS - Gritstone bio, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
EmeryVille,
United States
Type: Equity
GRTS price evolution
GRTS
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $52.17 | $43.64 | $65.28 | $30.78 |
| Short term investments | $4.81 | $3.91 | $16.29 | $54.41 |
| Net receivables | $0.2 | $0.21 | $0.23 | $0.3 |
| Inventory | ||||
| Total current assets | $60.71 | $51.85 | $87.44 | $90.82 |
| Long term investments | $4.7 | $5.29 | $5.29 | $5.29 |
| Property, plant & equipment | $76.53 | $79.14 | $84.12 | $89.86 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $81.83 | $85.36 | $90.33 | $96.4 |
| Total investments | $9.51 | $9.2 | $21.58 | $59.7 |
| Total assets | $142.54 | $137.21 | $177.77 | $187.22 |
| Current liabilities | ||||
| Accounts payable | $4.13 | $7.25 | $3.82 | $4.26 |
| Deferred revenue | $0.7 | $1.28 | $2.35 | $1.3 |
| Short long term debt | $7.16 | $6.81 | $6.9 | $6 |
| Total current liabilities | $23.9 | $25.87 | $27.34 | $23.38 |
| Long term debt | $95.33 | $96.47 | $97.87 | $89.3 |
| Total noncurrent liabilities | $96.45 | $97.38 | $98.58 | $89.85 |
| Total debt | $102.49 | $103.28 | $104.78 | $95.3 |
| Total liabilities | $120.35 | $123.25 | $125.92 | $113.23 |
| Shareholders' equity | ||||
| Retained earnings | -$723.34 | -$699.95 | -$659.56 | -$628.74 |
| Other shareholder equity | -$0 | -$0 | $0 | -$0.05 |
| Total shareholder equity | $22.19 | $13.96 | $51.85 | $73.98 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $65.28 | $17.31 | $104.57 | $170.06 |
| Short term investments | $16.29 | $116.39 | $108.35 | $1 |
| Net receivables | $0.23 | $0.66 | $1.39 | |
| Inventory | ||||
| Total current assets | $87.44 | $182.88 | $220.59 | $175.39 |
| Long term investments | $5.29 | $9.32 | $10.62 | |
| Property, plant & equipment | $84.12 | $38.82 | $44.54 | $43.45 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $90.33 | $57.88 | $57.52 | $46.18 |
| Total investments | $21.58 | $125.71 | $118.97 | $1 |
| Total assets | $177.77 | $240.75 | $278.11 | $221.57 |
| Current liabilities | ||||
| Accounts payable | $3.82 | $8.69 | $4.23 | $9.58 |
| Deferred revenue | $2.35 | $5.13 | $20.33 | $11.7 |
| Short long term debt | $6.9 | $5.29 | $7.48 | $5.87 |
| Total current liabilities | $27.34 | $34.8 | $39.96 | $26.99 |
| Long term debt | $97.87 | $19.35 | $18.94 | $19.23 |
| Total noncurrent liabilities | $98.58 | $35.17 | $22.06 | $27.84 |
| Total debt | $104.78 | $40.32 | $26.42 | $25.1 |
| Total liabilities | $125.92 | $69.97 | $62.02 | $54.83 |
| Shareholders' equity | ||||
| Retained earnings | -$659.56 | -$521.07 | -$401.38 | -$326.3 |
| Other shareholder equity | $0 | -$0.08 | -$0.07 | |
| Total shareholder equity | $51.85 | $170.78 | $216.09 | $166.74 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.92 | $1.74 | $10.38 | $1.56 |
| Cost of revenue | ||||
| Gross Profit | $0.92 | $1.74 | $10.38 | $1.56 |
| Operating activities | ||||
| Research & development | $20.81 | $33.04 | $32.94 | $32.76 |
| Selling, general & administrative | $7.7 | $8.5 | $7.92 | $7.41 |
| Total operating expenses | $28.51 | $41.54 | $40.86 | $40.17 |
| Operating income | -$27.59 | -$39.8 | -$30.48 | -$38.61 |
| Income from continuing operations | ||||
| EBIT | -$22.09 | -$39.09 | -$29.6 | -$37.44 |
| Income tax expense | ||||
| Interest expense | $1.3 | $1.3 | $1.22 | $0.99 |
| Net income | ||||
| Net income | -$23.4 | -$40.38 | -$30.82 | -$38.43 |
| Income (for common shares) | -$23.4 | -$40.38 | -$30.82 | -$38.43 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $16.34 | $19.95 | $48.21 | $4.04 |
| Cost of revenue | ||||
| Gross Profit | $16.34 | $19.95 | $48.21 | $4.04 |
| Operating activities | ||||
| Research & development | $127.18 | $111.4 | $97.49 | $88.64 |
| Selling, general & administrative | $28.78 | $28.97 | $25.93 | $21.41 |
| Total operating expenses | $156 | $140.37 | $123.42 | $110.05 |
| Operating income | -$139.65 | -$120.43 | -$75.21 | -$106.02 |
| Income from continuing operations | ||||
| EBIT | -$134.45 | -$118.45 | -$75.08 | -$105.31 |
| Income tax expense | ||||
| Interest expense | $4.04 | $1.24 | ||
| Net income | ||||
| Net income | -$138.49 | -$119.69 | -$75.08 | -$105.31 |
| Income (for common shares) | -$138.49 | -$119.69 | -$75.08 | -$105.31 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$23.4 | -$40.38 | -$30.82 | -$38.43 |
| Operating activities | ||||
| Depreciation | $4.91 | $5.05 | $5.71 | $5.48 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.47 | $3.25 | $2.82 | $2.96 |
| Total cash flows from operations | -$26.81 | -$33.57 | -$19.51 | -$31.09 |
| Investing activities | ||||
| Capital expenditures | -$0.03 | -$0.14 | -$0.19 | -$1.09 |
| Investments | -$0.85 | $12.45 | $38.49 | $19.37 |
| Total cash flows from investing | -$0.89 | $12.3 | $38.3 | $18.28 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $38.33 | $0.04 | $5.86 | $0.02 |
| Net borrowings | -$2.27 | -$0.06 | $9.86 | -$0.08 |
| Total cash flows from financing | $35.63 | -$0.38 | $15.72 | -$0.26 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $7.94 | -$21.64 | $34.5 | -$13.07 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$138.49 | -$119.69 | -$75.08 | -$105.31 |
| Operating activities | ||||
| Depreciation | $21.65 | $15.69 | $14.4 | $14.15 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $11.62 | $12.56 | $10.55 | $7.11 |
| Total cash flows from operations | -$121.65 | -$115.95 | -$50.68 | -$89.1 |
| Investing activities | ||||
| Capital expenditures | -$4.57 | -$5.87 | -$5.7 | -$3.52 |
| Investments | $106.91 | -$7.09 | -$112.85 | $69.46 |
| Total cash flows from investing | $102.34 | -$12.96 | -$118.55 | $65.95 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $8.93 | $65.51 | $117.21 | $135.91 |
| Net borrowings | $17.13 | $18.48 | -$8.45 | -$0.1 |
| Total cash flows from financing | $25.12 | $83.1 | $108.76 | $135.8 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $5.81 | -$45.81 | -$60.47 | $112.65 |
News
Fundamentals
| Market cap | $1.55M |
|---|---|
| Enterprise value | $51.87M |
| Shares outstanding | 117.79M |
| Revenue | $14.61M |
|---|---|
| EBITDA | -$107.08M |
| EBIT | -$128.22M |
| Net Income | -$133.03M |
| Revenue Q/Q | -52.89% |
| Revenue Y/Y | 25.08% |
| P/E ratio | -0.01 |
|---|---|
| EV/Sales | 3.55 |
| EV/EBITDA | -0.48 |
| EV/EBIT | -0.40 |
| P/S ratio | 0.11 |
| P/B ratio | 0.07 |
| Book/Share | 0.19 |
| Cash/Share | 0.44 |
| EPS | -$1.13 |
|---|---|
| ROA | -82.53% |
| ROE | -328.51% |
| Debt/Equity | 2.43 |
|---|---|
| Net debt/EBITDA | -0.64 |
| Current ratio | 2.54 |
| Quick ratio | 2.54 |